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Objective: Autologous platelet rich plasma is an advanced wound therapy used in hard-
to-heal acute and chronic wounds. To better understand the use and clinical outcomes
of the therapy, a systematic review of the published literature in cutaneous wounds was
performed. Methods: Electronic and hand searches for randomized controlled trials
and comparative group studies using platelet rich plasma therapy in cutaneous wounds
and published over the last 10 years was conducted. Eligible studies compared the
treatmenttostandardcareorotherinterventions.Allcitationswerescreenedandeligible
studies were assessed for validity, quality, and bias using accepted scoring methods. The
primary outcomes were effect of platelet rich plasma and control wound care on wound
healing and related healing measurements. Secondary outcomes related to healing such
as infection, pain, exudate, adverse events, and quality of life were also considered. The
meta-analysis utilized appropriate statistical methods to determine the overall treatment
effect on chronic and acute wound healing and infection. Results: The search terms
resulted in 8577 citations and after removing duplicates and screening for protocol
eligibility, a total of 24 papers were used. The meta-analysis of chronic wound studies
revealed platelet rich plasma therapy is signiﬁcantly favored for complete healing. The
meta-analysis of acute wounds with primary closure studies demonstrated that presence
of infection was reduced in platelet rich plasma treated wounds. Conclusions: This
systematicreviewandmeta-analysisofplateletrichplasmatherapyincutaneouswounds
showed complete and partial wound healing was improved compared to control wound
care.
Wound healing is a complex and dynamic process.1 Once a wound begins healing,
normally the process resolves with complete wound closure. However, healing of acute and
chronic wounds can become impaired by patient factors (ie, comorbidities) and/or wound
factors (ie, infection).2 Restarting a wound with impaired healing is difﬁcult because good
standard wound care does not always provide an improved healing outcome and often more
advanced therapies are employed.3-4
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Platelet rich plasma (PRP) gel is considered to be advanced wound therapy for chronic
and acute wounds. For more than 20 years, PRP gel has been used to stimulate wound
healing. Autologous PRP gel consists of cytokines, growth factors, chemokines, and a
ﬁbrin scaffold derived from a patient’s blood.5-6 The mechanism of action for PRP gel
is thought to be the molecular and cellular induction of normal wound healing responses
similar to that seen with platelet activation.6
Various studies evaluating PRP gel have been published over the years. Study design,
study populations, clinical outcomes, and methodological quality vary widely between
citations making concrete conclusions difﬁcult. Currently, there are 3 systematic reviews
on PRP therapy.7-9 One systematic review looked at tissue regeneration in randomized
controlledtrials(RCTs) in maxillofacialsurgery, chronic ulcers,and surgicalwounds.7 An-
other systematic review assessed healing of RCT diabetic ulcer studies.8 A third systematic
review was a poster presentation on the results of a systematic review of healing chronic
leg ulcers.9
Thesystematicreviewdescribedhereinwasperformed tospeciﬁcallyassessstudiesin
cutaneous skin wounds treated with autologous PRP gel and standard wound care (control
groups). Studies assessing healing information such as complete or partial wound healing,
time to heal, healing trajectory, velocity or rate, and wound size reduction were considered
critical for this systematic review.
METHODS
Selection criteria
For assessment of PRP treatment human intervention trials, only RCTs and comparative
studies (ie, treatment/intervention groups compared with controls, or a group with run-in
and comparable treatment data) published in peer-reviewed journals (articles, brief articles,
case studies, or letters) or presented at scientiﬁc meetings (abstracts) were considered.
Literature published between March 2001 and March 2011 was reviewed. Studies were
eligible if the participants had a cutaneous ulcer or wound (including dehisced wounds,
opensurgicalwounds,acute,orchronicwounds)thatweretreatedwithactivation-processed
PRP.Studiesofpatientswithmixedoriginwounds,subsetsofdifferentwoundtypes,surgical
wounds treated with PRP prior to closure and open, surgical wounds treated with PRP for
secondary closure were included. In addition, inclusion eligibility required PRP studies to
have a control treatment group (ie, placebo, wound care treatment). Noninferiority trials
in which 2 types of PRP treatment were compared were also eligible. Studies in which
the experimental group received other treatments were eligible provided that the control
group also received the same treatment or care so that confounding was avoided and the
systematic difference between the groups was only the primary intervention.
Studiesfocusingonburns,dentalorjawtreatment,bonefractures,orthopedicinjection,
or plastic surgery were excluded because of the different healing characteristics of these
wounds. Studies which used homologous/allogenic PRP procedures, lysates, freezing, or




Eligible studies had to report at least one wound-healing parameter as an outcome measure,
and/orassociatedparameterssuchasinfectionratesandincidence,painmeasures,exudation
management, quality-of-life measures, or net health beneﬁts. Examples of wound-healing
parameters included complete wound healing (proportions in each group or percentages
provided N for each group was reported; Kaplan-Meier and Cox regressions); wound
area reduction (mean or median, relative, absolute, or percentage); wound depth or volume
reduction (same parameters as for area); healing rate (change in area or wound dimension
per unit of time expressed in absolute terms or as a percentage), time to heal (mean or
median, expressed in days or weeks), or comparison of clinical signiﬁcant healing events,
such as reaching a reduction of 50% or more in area using Kaplan-Meier or Cox regression.
Outcomes could be unadjusted or adjusted for other covariates and factors, and compare
baseline and ﬁnal outcomes, or repeated measures. Follow-up for treatment/intervention
trials had to be a minimum of 2 weeks.
Search strategy
The Cochrane Library, Scopus, CINAHL, and PubMed databases were searched using
combinations of the following terms: platelet rich plasma, platelet rich plasma gel(s), PRP,
PRP gel(s), platelet gel(s), autologous growth factors, wound(s), chronic wound(s), chronic
nonhealing wound(s), open, cutaneous wound(s), dehiscence, dehisced, surgical wound(s),
diabetic ulcer, venous ulcer, pressure ulcer, sternal wound(s).
The journals Wounds, Worldwide Wounds and the clinical trial database clinicaltri-
als.gov were hand searched using the same terms. Identiﬁed reviews were also searched for
additional references to RCTs and comparative studies not previously captured. Narrative
reviews and editorials were examined for references of potential trials. Several experts in
the ﬁeld were also consulted for their knowledge of RCTs. After the initial selection of
studyabstractsappearedtomeetselectioncriteria,2reviewers(M.J.C.andC.P.F.)evaluated
each study in full to determine whether the study met the selection criteria and outcome
measures.
Numbers of citations for each search term entered (or combination of search terms),
numbers of papers fully examined, numbers of papers eligible for review, and numbers of
papers excluded with reasons were recorded. Duplicates were removed after conﬁrming
identicalpublicationinformation.Paperssuspectedofcontainingthesameresultspublished
elsewhere were reviewed to determine the originality of the results and which paper best
met the selection criteria outlined earlier.
Initial quality assessment
The quality of each study was assessed using a method reported by Downs and Black10 and
modiﬁedb yCarteretal. 11 Thescoringsheetcomprised5sections:reporting(qualityofhow
the study data were reported), external validity (the generalizability of the study), internal
validity (assessment of the potential for bias), internal validity (assessment of potential
confounders that may compromise the study), and power (assessment of the power of
the study to discriminate the effect sizes of the outcomes). Modiﬁcations of the original
methodincludedreplacementoftheexternalvaliditymodulewithanapproachbasedonthe
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number of patients who would likely have been excluded from the study.12 The section is
scoredaccordingtothecategoryofthestudy—satisfactory:3points;problematic:2points;
unsatisfactory:1point.Thepowermodulewastruncatedwiththefollowingscoringscheme:
reported sample size calculation (for RCTs): 1 point; reported more than 1 calculation: 2
points; no reporting of sample size calculation: 0 points; power reported for at least 1
clinically important effect (for comparative studies): 1 point; reported for all clinically
important effect: 2 points; no reporting of power for clinically important effects: 0 points.
The total score possible was 29 points.
Bias was summarily reported using the SIGN grade methodology, which is deﬁned as
follows: ++ applies if all or most criteria from the checklist are fulﬁlled or where criteria
are not fulﬁlled, the conclusions of the study or review are thought very unlikely to alter;
+ applies if some of the criteria from the checklist are fulﬁlled or where criteria are not
fulﬁlled or are not adequately described, the conclusions of the study or review are thought
unlikely to alter; − applies if few or no criteria from the checklist are fulﬁlled or where
criteria are not fulﬁlled or are not adequately described, and the conclusions of the study or
review are thought likely or very likely to alter.13 The grade assignment of study bias was
accomplishedbytakingthetotalscoreoftheexternalvalidityandinternalvalidity(biasand
confounding) sections of the quality assessment, and scoring as follows: 0 to 8 points (−);
9 to 12 points (+); 13 to 16 points (++). Scoring was carried out independently by M.J.C.
and C.P.F. who then reconciled any discrepancies in subsequent discussion. Final grade
assignments took into consideration serious ﬂaws or inconsistencies,or other attributes that
could decrease or increase initial grade assessment.14
Data extraction and analysis
Outcomes were categorized by type, and for each one, the pretreatment and posttreatment
numbers,median,ormeanvalues(SD)wereextractedwherepossible.Toensurethatcorrect
numbers were obtained, this process was performed by M.J.C. and checked by C.P.F. No
investigators were contacted for further clariﬁcation. The number needed to treat was
calculated for studies reporting complete wound healing, and where protocol analyses were
used, the data were updated to reﬂect an intent-to-treat analysis. Data were imported into
software (Revman 5.0 Information Management, Nordic Cochrane Centre, Copenhagen,
Denmark) to calculate 95% conﬁdence intervals and P values using ﬁxed-effect models
where possible. The Mantel-Haenszel method was used with risk difference as the effect
measure in the case of dichotomous events, and the inverse variance method was used
with the weighted mean difference (WMD) as the effect measure in the case of continuous
(interval) data.
Grading
After data extraction and initial quality assessment were complete, important and critical
outcomes were agreed upon using consensus and quality assessment. Summary of ﬁndings
for studies comparing use of PRP treatments against standard care were assessed using the
GRADE system for each type of wound.14-16
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Meta-analysis
Meta-analysis (statistical pooling) was carried out on those studies that had the following
compatible outcomes and reasonable clinical homogeneity: (1) complete wound healing;
(2) superﬁcial infection; and (3) pain reduction. Results from RCTs were pooled separately
from other comparative studies. For dichotomous events, a ﬁxed-effect model was em-
ployed that used the Mantel-Haenszel method with risk difference as the effect measure for
easier interpretation. In the case of continuous (interval) data, a ﬁxed-effect model was also
employed using the inverse variance method with the effect measure of WMD (weighted
mean difference). Statistical heterogeneity was assessed using the I2 (inconsistency) statis-
tic,whichindicatesthepercentagevariationbetweenstudiesthatisaresultofheterogeneity
rather than chance.17 If the I2 (inconsistency) value was 30% or higher, meta-analysis was
also conducted using a random effects model.
RESULTS
Study selection
The protocol search terms (see “Methods”) resulted in 8577 citations, the majority of
which were duplicates (Fig 1). Potentially eligible studies (n = 68) were identiﬁed
per protocol criteria.18-82 There were 44 papers excluded for one or more of the fol-
lowing reasons: narrative review, noncomparative study and/or case series, confounded
with other treatments, cost-effectiveness study, insufﬁcient outcome data reported, non-
cutaneous wounds, generic wound care research paper, reported outcomes did not in-
clude protocol eligibility criteria, non-PRP systematic review, freeze-dried PRP, allo-
genic PRP, frozen platelets, letter to editor discussing ineligible RCT, survey, and animal
study.39-82
Twenty-one studies on the subject were identiﬁed and used (Fig 1).18-38 In addition,
3 systematic reviews on PRP use were found and detailed in the “Discussion” section.7-9
The reviewers agreed on 95.8% of the quality analysis items scored with a kappa of 0.899.
Eligible PRP publications consisted of 12 RCTs, 3 cohort studies, 5 comparative study
designs, and 1 retrospective analysis with propensity scoring. Table 1 describes the study
design, enrolled subjects, wounds, and wound care treatments of each. Within the eligible
studies, 3 main types of wounds which were treated with PRP were identiﬁed: (1) open,
chronic wounds,18-24 (2) acute surgical wounds with primary closure,25-35 and (3) acute
surgical wounds with secondary closure.36-38
Quality analysis
Three citations with the least bias were RCTs in primary closure acute wounds25,28,30
(Table 2). Study quality varied greatly between papers. Chronic wound studies had 2 RCTs
score − and 3 comparative studies score +. Studies in acute wounds with primary closure
h a d3R C T ss c o r e++, 3 score − and 5 comparative studies score +. Acute wounds
with secondary closure studies had 2 RCTs score + and 1 comparative study score −
(Table 2).
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Figure 1. Systematic review of platelet rich plasma literature, March 2001
to March 2011. Template from Moher D, Liberati A, Tetzlaff J, Altman DG;




Outcomes associated with wound healing directly (ie, healing, size reduction) or indirectly
(healing impairments, complications) were analyzed. These outcomes were judged to be
critical or important since time to heal, complications (ie, amputations or life-threatening
situations), and quality of life (QoL) can signiﬁcantly impact wound healing. Data analyses



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Of 4 RCTs, 2 were statistically signiﬁcant for complete wound healing compared to saline
gel or no topical treatment.19-20 It should be noted that the 2 studies that did not detect
signiﬁcance at weeks 5 and 8 did have statistically signiﬁcant wound area reductions
comparedtosalinegauzeornotopicaltreatmentsuggestingthatalongerstudyperiodwould
have detected complete healing18,21 (Table 3). A non-RCT, comparative designed study
showed consistently higher signiﬁcant relative risks for complete wound healing in favor
of platelet releasate compared to no topical treatment based on 26,599 subjects23 (Table 3).
Two RCT studies evaluated time to heal and both showed signiﬁcant improvements in PRP-
treated subjects versus saline gel or no topical treatment19-20 (Table 3). Platelet rich plasma
subjects in a historical cohort study required signiﬁcantly fewer days to complete healing
compared to hyaluronic acid–dressed wounds24 (Tables 3 and 4). Two RCT studies showed
statistically signiﬁcant differences in wound area reduction compared to saline gauze or no
topical treatment controls.18,21 Similarly, a non-RCT, comparative study showed signiﬁcant
area and depth reductions with 2.5- to 3.5-fold decrease in time to reach 50% compared to
pretreatment moist wound care controls.22 Adverse events were consistently lower for PRP
groups than for controls of saline gauze, saline gel or no topical treatment.18-20
Acute primary closure wounds
Only 2 RCT and 2 non-RCT comparative studies speciﬁcally looked at wound-healing
outcomes (Tables 3 and 5).26,28,31,34 One RCT detected a statistically signiﬁcant difference
incompletewoundhealingforPRPcomparedtonotopicaltreatmentduringashort2-week
follow-up28 (Tables 3 and 5). The other RCT study evaluated wounds with impaired wound
healingatday50andfoundnodifferencebetweennotreatmentandPRPgelsuggestingthat
PRP therapy does not impede wound healing.26 In all studies, PRP therapy had statistically
fewer wound-healing disturbances and wound postoperative complications than the no
treatment control counterparts26,31,34 (Table 3).
Six different infection sites and postoperative complications were considered espe-
cially important criteria and were addressed in 1 RCT and 4 comparative studies.25,31,33-35
Twostudiesfoundinfectionratesthatwerenotsigniﬁcantlydifferentcomparedtonotopical
treatment,25,33 however, chest, superﬁcial and deep infections and postoperative complica-
tions were signiﬁcantly lower in PRP-treated study subjects than in no topical treatment
controls25,31,33-35 (Tables 3 and 5). Infection was signiﬁcantly increased in control groups
than that in PRP groups in all but 1 study (Tables 3 and 5).
Exudate, drainage, and hematomas were evaluated in 2 RCT and 2 compara-
tive studies.26,30-31,33 In 1 RCT, PRP-treated wounds had signiﬁcantly fewer large area
hematomas than no topical treatment control wounds, thus reducing a potential source for
infection.26 The amount and presence of drainage was statistically signiﬁcantly reduced in
the PRP-treated wounds in all studies compared to controls of saline spray or no topical
treatment30-31,33 (see Tables 3 and 5).
Postoperative,general,resting,andactivepain,aswellasnarcoticusewasassessedin5
RCTstudiesand1comparativestudy.26-30,32Although4RCTstudiesdidnotshowstatistical
differences in mean postoperative pain, 1 study did27 (Tables 3 and 5). Postoperative pain
for both leg and chest were signiﬁcantly reduced for the PRP-treated wounds for 30 days,
400CARTER ET AL
but not for no topical treatment control wounds27 (Table 3). A comparative study also
showed intravenous narcotic use was statistically lower in PRP-treated subjects than in no
topical treatment controls indicating less pain was present32 (Table 3).
Acute secondary closure wounds
Complete wound closure was found to be statistically faster in PRP treated wounds com-
pared to Bacitracin or no topical treatment in both a RCT and comparative study37-38
(Tables 3 and 5). The healing velocity of PRP-treated wounds was signiﬁcantly greater
than Bacitracin control.38 In 1 RCT, the mean time PRP-treated wounds required to
partially heal in preparation for deﬁnitive surgery was not only signiﬁcant, but almost
half of that of Vaseline gauze controls36 (Tables 3 and 5). The PRP group healing rates
and wound area and volume reductions were statistically signiﬁcant in all studies36-38
(Tables 3 and 5). One RCT study assessed VAS pain scores at 3 weeks and found
PRP-treated wounds had signiﬁcantly less pain than Vaseline gauze controls36 (Tables 3
and 5). One RCT administered the SF-36 tool at week 3 to evaluate wound treatment effect
on patient QoL and showed PRP-treated subjects had signiﬁcantly better QoL scores than
subjects with no topical treatment37 (Table 3).
Meta-analysis
A meta-analysis was performed on chronic wound RCTs studies using PRP and standard
wound care to analyze the impact of the therapies on complete wound healing.18-21 Using
the ﬁxed-effect model for complete wound healing, the results were signiﬁcantly in favor of




reduction, however, could be performed. Acute wounds with primary closure comparative
studies evaluating superﬁcial infection were modeled using random effects.31,35 The results
were in favor of the PRP therapy to reduce infection but not signiﬁcant compared to no
topicaltreatment(Fig3).Fortheacutewoundwithprimaryclosure,RCTstudiesevaluating
postoperative pain were modeled using random effects.26-27,30 The results were in favor of
the PRP therapy to reduce pain but not signiﬁcant compared to saline spray or no topical
treatment (Fig 4).
DISCUSSION
There were 21 publications that were RCT or comparative non-RCT designs in this sys-
tematic review. Given the physiological and healing differences between acute and chronic
wounds, the citations were divided by study design and by type of wound prior to review
and meta-analysis. The primary outcome assessed in this systematic review was complete
healing. In both chronic and acute wound studies, complete wound closure was more likely
in wounds treated with PRP therapy. Similar partial healing and wound area/volume re-


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the therapy is discontinued once the wound begins healing. This meta-analysis and other
systematic reviews show PRP has sufﬁcient efﬁcacy to stimulate healing in stalled wounds.
One systematic review concluded that the percentage of total healing in PRP-treated skin
ulcers consistently increased compared to controls.7 The meta-analysis of chronic wound
studies conﬁrmed the use of PRP treatment favored complete healing compared to control
care. Other systematic reviews on PRP therapy reached the same conclusions.7-9 One sys-
tematic review went so far as to conclude that based on the meta-analysis and scientiﬁc
evidence regarding consistent favorable outcomes, PRP is a treatment of choice for the
topical care of wounds.9
Because nonhealing wounds incur expenses as well as run a higher risk of complica-
tions, the sooner a wound can heal or be ready for surgery, the less likely the wound will
become more problematic.83 The data suggest that PRP therapy can be extremely cost-
effective in chronic wounds and it may also be effective in certain acute wounds. A recent
study found that a speciﬁc PRP gel was the most cost-effective over a 5-year period of time
compared to other advanced wound therapies in the treatment of diabetic foot ulcers.84
From a clinical point of view, the decrease in complication risks and expenses with healing
impacts patient health, ﬁnances, and QoL. From a payor’s perspective, achieving closure at
25% to 50% faster rate than control care treatment alleviates the expenses of a longer and
more problematic treatment course resulting in a beneﬁt for both patient and payor.
Infection and exudate were evaluated in many acute primary closure wound studies
because both can delay healing. Overall, infection rates appear to be lower in PRP-treated
subjects. The meta-analysis of the RCT studies conﬁrmed the infection rates were lower
when PRP treatment was used compared to control care although not signiﬁcantly so.
Because increased exudate in wounds can be a precursor to infection, the presence of
the exudate is closely documented. As seen in this review, in both RCT and non-RCT
comparative studies, the amount and presence of drainage was statistically signiﬁcantly
reduced in the PRP-treated wounds suggesting potentially fewer infectious complications.
Decreasing exudate and infection risks are beneﬁcial for the patient, the wound, and the
clinician and should improve the healing rate. Obvious beneﬁts of no or reduced topical
and systemic antimicrobials are limiting exposure to microorganisms, reduction in ex-
penses and improved patient QoL. Payors know that wounds that are infected or heavily
colonized do not heal as quickly as wounds that are not contaminated, saving costs and
time.2
Pain is often associated with wounds, but because of the subjective nature of the sen-
sation, determining the impact of wound care therapies on different types of pain, levels of
pain, and when pain is assessed can be difﬁcult. Pain outcomes appeared mixed with some
studiesreportingnodifferencebetweentreatmentsandothersshowingsigniﬁcantlystatisti-
cal differences favoring PRP treatment. Objective use of measured intravenous narcotic use
and SF-36 tool for QoL more clearly demonstrate PRP-treated subjects had signiﬁcantly
better QoL scores and fewer required narcotic medication. This suggests the therapy may
result in less wound pain. The meta-analysis suggests PRP therapy may positively impact
the patient by reducing pain. Presence of persistent pain can impair healing as well as affect
patient QoL.85 Reduction in pain allows clinicians to prescribe less addictive and lower
risk analgesics as well as fewer drug interactions. While payors sometime underestimate
the impact pain has on healing and QoL, the expense of high level pain medication adds up
quickly.
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The quality of the eligible studies varied widely as shown through multiple scoring
methods. Using several methods together allowed the authors to quickly and consistently
evaluate the strengths and weaknesses of each paper. Many RCTs were lower in quality,
higher in bias, and had more serious limitations than many comparative or cohort studies.
This emphasizes the need to evaluate the quality and bias of published studies in addition
to the study design.
One limitation of this systematic review was that while many citations evaluated the
impact of PRP treatment on wound healing, there are many methods and deﬁnitions for
determiningandmeasuringwoundhealing.Astheliteraturepoolgrows,moresubcategories
(ie, by PRP product type) can be assessed.
On the basis of the last 10 years of research, the results of this systematic review and
meta-analysissuggestthatPRPtherapycanpositivelyimpactwoundhealingandassociated
factors such as pain and infection in both chronic and acute cutaneous wounds.
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